Anti-VEGF therapies in the clinic
KL Meadows, HI Hurwitz - Cold Spring …, 2012 - perspectivesinmedicine.cshlp.org
KL Meadows, HI Hurwitz
Cold Spring Harbor perspectives in medicine, 2012•perspectivesinmedicine.cshlp.orgThe development and use of antiangiogenesis agents, particularly those targeting vascular
endothelial growth factor (VEGF), has become an integral component of anticancer
regimens for many tumor types. This review is intended to highlight some of the most
important clinical successes and failures of anti-VEGF therapies, and where possible, to
suggest important lessons that have been learned. This review emphasizes data from
agents that have been FDA approved and/or have completed phase III studies.
endothelial growth factor (VEGF), has become an integral component of anticancer
regimens for many tumor types. This review is intended to highlight some of the most
important clinical successes and failures of anti-VEGF therapies, and where possible, to
suggest important lessons that have been learned. This review emphasizes data from
agents that have been FDA approved and/or have completed phase III studies.
The development and use of antiangiogenesis agents, particularly those targeting vascular endothelial growth factor (VEGF), has become an integral component of anticancer regimens for many tumor types. This review is intended to highlight some of the most important clinical successes and failures of anti-VEGF therapies, and where possible, to suggest important lessons that have been learned. This review emphasizes data from agents that have been FDA approved and/or have completed phase III studies.
perspectivesinmedicine.cshlp.org
